Zhong Tong Finance APP news, Baiyunshan (00874) released its interim performance for the six months ending June 30, 2024. During this period, the group achieved operating revenue of 41.043 billion yuan (RMB, same below), an increase of 2.68% year-on-year; net income attributable to the parent company of 2.55 billion yuan, a decrease of 9.31% year-on-year; and basic earnings per share of 1.568 yuan.

The announcement stated that during this reporting period, the group focused on the following key work:

Aggregating resources, strengthening product varieties, and consolidating the foundation for the development of the Dahan Medicine sector. During this reporting period, the Dahan Medicine segment continued to cultivate and expand the market, steadily promoted the "1+4" marketing integration, and promoted the steady development of the end market. It leveraged the advantages of brand synergy, increased the promotion of famous and high-quality products, and enhanced brand influence. It promoted the organic integration of the digital economy and the pharmaceutical and health industry, opened up new marketing paths, and promoted the continuous development of the e-commerce sector. It increased its efforts in international expansion, accelerated the fashionable and international development of traditional Chinese medicine products. During this reporting period, the sales revenue of products such as She Dan Chuan Bei Pi Pa Gao, Mi Lian Chuan Bei Pi Pa Gao, Feng You Jing, Xiao Chai Hu Ke Li, Zi Shen Yu Tai Wan, intravenous cefuroxime sodium, Zhuang Yao Jian Shen Wan, Amikacin and Chlorphenamine Capsules, Qing Kai Ling series, Yin Yin Qing Fei combined preparation, Yin Yin Qing Fei Gao achieved rapid growth compared to the same period last year.

Expanding the market, developing new products, and enhancing the development momentum of the Dajiankang sector. In the first half of 2024, the Dajiankang sector focused on market demand, cultivated diversified new products, comprehensively developed the ready-to-drink market, continued to exert efforts in the e-commerce channel, and explored international markets, striving to promote recovery-oriented growth and reduce the impact of macroeconomic fluctuations, rainy weather, and intense industry competition. In the first half of 2024, Dajiankang launched new products such as rose flavor, small blue orchid flavor, folded ear root flavor, and yuan flavor cooling tea, further enriching the product matrix. It carried out the release of the WALOVI English logo for Wanglaoji, accelerating its international market layout.

Strengthening construction, shaping the brand, and exploring the development space of the Damedical sector. In the first half of 2024, Baiyunshan Hospital established a new internal department focused on "neurology, respiratory and chronic disease rehabilitation" as its main diagnosis and treatment direction. It accelerated the construction of three major centers, namely the Chest Pain Center, Trauma Center, and Stroke Center, and comprehensively strengthened the overall discipline construction of the hospital to continuously enhance its comprehensive strength. The Baiyunshan Traditional Chinese Medicine Hospital has completed and passed the acceptance of the internal medicine ward, traditional Chinese medicine gynecology outpatient, traditional Chinese medicine surgery outpatient, and traditional Chinese medicine orthopedics outpatient departments. Run Kang Yuezi Company continuously improves its brand influence by increasing publicity and marketing efforts, deepening cooperation in the upstream and downstream industries, and continuously improving occupancy rates.

Strengthening scientific research, promoting innovation, and continuously improving scientific research and development capabilities. In the first half of 2024, the group's research and development expenses totaled 0.391 billion yuan. It obtained 12 drug-related approvals, including Tadalafil tablets, Glanzit tablets, and Ke Gan Li Yan oral solution. Among them, there were 6 approvals for chemical raw materials and preparation production, 4 supplementary applications for consistency evaluation, and 2 clinical approvals. Gansu Guangyao Baiyunshan Traditional Chinese Medicine Technology Co., Ltd. and Baiyunshan Biological have obtained provincial qualifications. The company and its joint ventures have won a total of 7 international-level awards and national-level association awards. Among them, the project "Integrated Innovation and Support System for Quality Testing of Traditional Chinese Medicine and Its Application" by Baiyunshan and Huang Company won the second prize of the National Science and Technology Progress Award, and Baiyunshan Pharmaceutical Factory's high-quality traditional Chinese medicine for treating viral respiratory tract infections, Anti-viral Soft Capsules, won the Gold Award at the 49th Geneva International Invention Exhibition.